AI Summary
The article discusses the challenges in treating pancreatic ductal adenocarcinoma, noting that many patients still experience metastatic recurrence even after surgery and post-operative therapy. It highlights the importance of tailoring post-operative treatments to improve outcomes. The use of artificial intelligence to enhance precision oncology in customizing treatment plans is suggested as a way to circumvent human limitations in tailoring therapies for pancreatic ductal adenocarcinoma.
Pancreatic ductal adenocarcinoma is rightly considered an ab initio systemic disease, with >50% of patients presenting with metastatic disease at the time of diagnosis.1 Even among those who appear to have localized disease and undergo surgery and post-operative therapy, metastatic recurrence remains highly prevalent. Indeed, in the ‘not-yet-clearly-metastatic’ setting of post-operative treatments, the most effective regimens have proven to be those most active in the advanced setting as well. In this regard, the potential for tailoring post-operative treatments remains of utmost relevance.